BioSpace News Archive

Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.

Although anti-retroviral therapies have come a long way in turning HIV into being treated like a chronic, manageable disease, researchers are still attempting to find something that might be considered a cure, which would completely eradicate the virus. Researchers from University of Texas Medical Branch at Galveston may have found a way.

A generic version of Gilead’s Truvada for PrEP is due on the market next year. The activists argue that will be a better alternative price wise.

UsAgainstAlzheimer’s recently published a research report providing an overview of the clinical trial pipeline for Alzheimer’s disease. George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s, took time to speak with BioSpace about the report and current approaches to battling the disease.

Gene therapy companies could be continued M&A targets for larger ones as more and more companies are looking to broaden their therapeutic focus with potential one-time therapies for various diseases.

Biopharma companies from across the globe share business and development updates.

Orion Biotechnology Canada Ltd. announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB).

MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.

Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have successfully developed an innovative nanocarrier derived from green tea catechins, which can deliver anti-cancer drugs in a targeted and effective fashion.

Codexis, Inc. announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effective August 19, 2019.